AstraZeneca Q1: Sold 1.375M Shares, Bought $131.15M Stake; Leads 5+ Late-Stage Lymphoma Drugs
T Rowe Price Equity Income Fund sold all 1.375M AstraZeneca shares (–0.77% portfolio impact) then bought 665,000 AstraZeneca shares worth $131.15M (0.83% of portfolio) in Q1 2026. AstraZeneca leads five late-stage follicular lymphoma therapies among 45+ active programs as its CEO warns German price controls may delay new drug launches.
1. Fund Position Changes
T Rowe Price Equity Income Fund overhauled its Q1 2026 holdings in AstraZeneca by selling all 1,375,000 shares—cutting 0.77% of its portfolio—before acquiring a new position of 665,000 shares valued at $131.15M, representing 0.83% of the fund’s net assets.
2. Expanding Follicular Lymphoma Pipeline
AstraZeneca is one of more than 45 companies with over 50 therapies in development for follicular lymphoma, with five of its candidates in late-stage trials. The company is advancing targeted, oral and patient-centric approaches including kinase inhibitors, protein degraders and immune-mediated treatments.
3. German Pricing Risk Could Delay Launches
AstraZeneca’s CEO cautioned that Germany’s proposed pharmaceutical spending caps could jeopardize the timely rollout of its upcoming drugs, potentially deferring launches in a key European market and impacting future revenue growth.